Merck acquires Calporta Therapeutics for its autophagy-boosting molecules

Saturday, November 30, 2019 - 12:24 in Health & Medicine

Calporta is developing TRPML1 agonists for neurodegenerative diseases and lysosomal storage disorders

Read the whole article on C&EN

More from C&EN

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net